(Reuters) - "We will continue to protect our intellectual property," Novartis spokesman John Gilardi said on Thursday.
Novartis has a compound patent on Femara until 2011 and filed a patent infringement lawsuit against Mylan's generic version in 2006.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment